Swinnzea Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 0.18 M
- Company Age 5 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 185.45%
- Profit Growth 676.93%
- Ebitda 201.94%
- Net Worth 79.44%
- Total Assets 108.99%
About Swinnzea Pharmaceuticals
Swinnzea Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 March 2019 (Five years and ten months 29 days old ). Its registered office is in Bangaluru, Karnataka, India.
The Corporate was formerly known as Sebakind Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.18 M, as per Ministry of Corporate Affairs (MCA) records.
Sathisha Raju and Jayalakshmi Murthy serve as directors at the Company.
Company Details
-
Location
Bangaluru, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230KA2019PTC122375
-
Company No.
122375
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
14 Mar 2019
-
Date of AGM
17 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Swinnzea Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sathisha Raju
|
Director | 14-Mar-2019 | Current |
|
Jayalakshmi Murthy
|
Director | 05-Aug-2022 | Current |
Financial Performance of Swinnzea Pharmaceuticals.
Swinnzea Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 185.45% increase. The company also saw a substantial improvement in profitability, with a 676.93% increase in profit. The company's net worth Soared by an impressive increase of 79.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Swinnzea Pharmaceuticals?
In 2021, Swinnzea Pharmaceuticals had a promoter holding of 83.40% and a public holding of 16.60%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Swinnzea Pharmaceuticals?
Swinnzea Pharmaceuticals has a workforce of 13 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Swinnzea Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Swinnzea Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
